All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-09-16T11:12:12.000Z

How can we apply MRD guidelines to low-intensity therapy in AML?

Sep 16, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in acute myeloid leukemia.

During a meeting of the AML Hub Steering Committee, held on May 8, 2024, Jeffrey Lancet chaired a discussion on the question: How can we apply minimal residual disease (MRD) guidelines to low-intensity therapy in acute myeloid leukemia (AML)? The discussion featured contributions from Gail Roboz, Naval Daver, and Uwe Platzbecker.

The steering committee members discuss how MRD negativity can serve as a prognostic tool for guiding treatment decisions in AML, including low-intensity therapy (e.g., hypomethylating agents, venetoclax), maintenance therapy (including gilteritinib), transplantation, treatment modification, and extended drug holidays, in both fit and older/frail patients. The steering committee members highlighted the limitations of existing MRD assessment methods, such as the sensitivity of flow cytometry, assay quality, NPM1, FLT3, NGS PCR assays, and RNA fusion panels. The group also previewed the upcoming European LeukemiaNet risk guidelines on MRD monitoring and potential opportunities to learn about experiences in other diseases, such as acute and chronic lymphoblastic leukemia. 

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
7 votes - 37 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox